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In LCC, IHC has been unveiling the same lineage heterogeneity [6] [7] [8] [9] [10] [11] [12] [13] , as previously demonstrated by means of electron microscopy 14, 15 , indicating that squamous, NE and, especially, glandular cell differentiation underlie most LCC, whilst completely uncommitted tumors are decidedly uncommon 6, 10, 11, 13, 16, 17 . Among the many IHC biomarkers aimed at discovering the hidden face of LCC 6, 10, [17] [18] [19] , thyroid transcription factor-1 (TTF1) 20, 21 , and Δ(delta)Np63 (henceforth, simply p40) [22] [23] [24] [25] [26] , proved the best diagnostic biomarkers to highlight ADC and SQC lineages, respectively 3, [27] [28] [29] [30] [31] [32] . Although the duet TTF1/p40 remains the most reliable predictor of cell lineage and therefore of the ultimate diagnosis in lung cancer 3, 4, 27, 33, 34 , some uncertainty may arise in undifferentiated tumors when faced with complete absence of both biomarkers (null phenotype: TTF1-/p40-) or focal labeling for squamous differentiation biomarkers, such as p40, in otherwise TTF1-negative tumors (unclear phenotype: TTF1-/p40±).
A growing body of information is accumulating about the occurrence of non-random genetic alterations in defined subtypes of lung cancer 4, [35] [36] [37] [38] [39] [40] [41] . New actionable driver genes are emerging from the molecular landscape of lung cancer, especially when using multiplexed or unbiased technologies of next generation sequencing (NGS) [42] [43] [44] [45] [46] [47] . NGS/T-NGS data or molecular investigations on LCC are relatively scant 16-18, 48, 49 for either novelty of these technologies or progressive disappearance of such histological type 11, 13 . Recent surveys on the subject, however, have provided strong evidence that many, if not all, LCC display genetic profiles (including microRNA expression) 18 mostly aligned with ADC and/or SQC 16, 17, 49 , but the approach has been to correlate a-priori-defined IHC diagnoses with underlying gene alterations rather than to interpret IHC profiles according to the relevant mutation portrait.
This study was aimed at establishing the relationship between genotype and phenotype in LCC also according to tumor categorization of the current 2015 WHO classification by comparing their molecular profile assessed by unsupervised T-NGS with stochastically defined IHC categories according to biomarkers of glandular and squamous cell lineages (TTF1 and p40) and then at a posteriori dissecting tumors on the basis of the preferential distribution of gene mutations between ADC and SQC.
Materials and methods

Design of the study
We designed and conducted a two-phase investigation to test the relationship between genotype of LCC according to T-NGS analysis and phenotype according to TTF1 and p40 IHC, thereby providing a biological rationale to the diverse diagnostic algorithms with particular reference to null and unclear phenotypes. To this regard, in the first phase, we accomplished an unsupervised T-NGS analysis on 30 LCC by using a large panel of 50 oncogenes and tumor suppressor genes recurrently altered in human cancers and compared molecular results with clinico-pathological characteristics of patients, including survival. In the second phase, we attributed the relevant gene mutations to the diverse IHC-prioritized diagnostic algorithms on the basis of their own preferential distribution in the two major categories of lung cancer, i.e. ADC and SQC, to molecularly validate the role of these biomarkers in constructing decisional algorithms even in undifferentiated tumors. respectively.
Patients and tumors
Ethics
The study was notified to and approved by the independent ethics committee of the "Fondazione IRCCS Istituto Nazionale Tumori", Milan, Italy (accession number INT-145/14).
All patients gave their written consent for diagnosis and research activities when they were admitted to the hospital.
Sequencing, fluorescence in situ hybridization and immunohistochemistry procedures
A detailed description of molecular and IHC laboratory procedures we pursued in this investigation, including DNA extraction and quantification, fluorescence in situ hybridization (FISH), T-NGS and Sanger analyses and the relevant antibodies, is reported in S1_Molecular&IHC method and Table 2 , respectively. Cut-off of 10% for focal expression of p40 was chosen on the basis of recently refined IHC methods 1, 3, 27, 58 . The same paraffin tumor blocks were used for every type of analysis, whether sequencing or IHC. In particular, FISH analysis for FGFR1 gene was accomplished in the subsets of tumor patients with null (TTF1-/p40-) or unclear (TTF1-/p40±) phenotype according to its preferential, albeit not exclusive, prevalence in squamous cell carcinoma as compared to adenocarcinoma [59] [60] [61] . tumor cells) (p=0.109) (S1_Table1 and S1_Fig 1). To ensure accuracy, BRAF, EGFR, KRAS, NRAS, PIK3CA, RET, STK11 and TP53 mutations were re-sequenced with Sanger method (see also S1_Molecular&IHC method).
Statistical analysis
Results
Mutation landscape of large cell carcinoma
Phenotypic categories of large cell carcinoma
Five different diagnostic algorithms were obtained by stochastically crossing TTF1 and p40 IHC according to positive, negative and focal categories ( Table 4 ). No significant relationship was found between IHC categories and morphologic classification of LCC.
Relative to IHC, TTF1 decoration varied from 20% to 100% tumor cells (mean±SD: 61.3±34.5%), while p40 ranged from 2% to 100% tumor cells (mean±SD: 34.0±39.6%). No significant differences were observed between p40 polyclonal and monoclonal antibody.
Additional IHC work-up with p63 and CK7 did not provide useful information for better unveiling null or unclear phenotype (see also S2_Result). Representative features of TTF1 and p40 decoration in the diverse phenotype combinations are presented in Fig 1, where p63 and CK7 stains are also included as picture insets.
Genotypic and phenotypic correlations of large cell carcinoma
The distribution of 27 gene-mutated tumor patients among the five categories based on stochastically crossing TTF1 and p40 IHC is shown in Table 4 , which includes 6 tumors with TTF1+/p40-phenotype, 1 tumor with TTF1+/p40± phenotype, 3 tumors with TTF1-/p40+ phenotype, 13 tumors with null TTF1-/p40-phenotype and 4 tumors with unclear TTF1-/p40± phenotype.
Taking advantage of the molecular distribution, all tumors negative or only focally positive for p40, regardless of TTF1 IHC results (categories TTF1+/p40-, TTF1+/p40±, TTF1-/p40± and TTF1-/p40-) were molecularly akin to ADC (LCC-favor ADC), whereas TTF1-/p40+ category was molecularly in keeping with SQC for presenting TP53 mutations only along with FGFR1 amplification in two of three cases (Fig 2 A,B) , (LCC-favor SQC). FGFR1 FISH analysis was extended to the 13 tumors with null (TTF1-/p40-) and the 4 tumors with unclear (TTF1-/p40±), finding that there was only one out of 17 (6%) tumor samples to exhibit FGFR1 gene amplification (p=0.046) (Fig 2 C,D) ..
The 11 tumors harboring multiple mutations corresponded to ADC patients with TTF1+/p40-, TTF1-/p40-or TTF1+/p40± phenotype in 5, 5 and 1 tumor, respectively.
Patient survival correlations
General survival of the 30 LCC patients under evaluation for both OS and DFS is shown in S2_Fig 2. Tumor patients expressing 3 mutations or more experienced a shorter OS (p=0.001) and DFS (p=0.007) independent of tumor stage (p=0.827) in comparison with wild type or up-to-2-gene-mutated patients (Fig 3) . Other factors affecting OS and DFS were tumor stage, tumor size and pleural invasion, but none of them or the number of mutations per patient emerged as independent prognostic factors at multivariate analysis.
Categorization of LCC according to the diverse IHC diagnostic algorithms or morphologic subclasses failed to demonstrate any survival implication.
Discussion
In this study, we performed a mutation-based classification of LCC by taking advantage of T-NGS for a large number of tumor suppressor genes and oncogenes repeatedly altered in human cancers. This was compared with a morphologic classification and unsupervised IHC diagnostic algorithms of tumors resulting from stochastically crossing two highly specific biomarkers of glandular and squamous cell differentiation, namely TTF1 and p40, respectively. At variance with similar recent works on LCC where tumor diagnostic categories were assigned before genotyping according to a relatively small number of gene mutations 16-18, 48, 49 , we designed this two-phase investigation to minimize not only an a priori interpretation of undifferentiated tumors according to decisional IHC algorithms suited for conventional NSCLC but also to rule out "aberrant/illegitimate" acquisition of biomarkers by undifferentiated tumor cells due to loss of relevant cell fate niches or unfaithful expression of nuclear transcription factors. As there were some limitations to the study due to the relatively small number of LCC under evaluation, the lack of SQC-specific mutations in the 50-gene panel we used for the analysis (such as DDR2, KEAP1 and NFE2L2/NRF2 ), some overlap in the mutation scenario between ADC and SQC and the uncertain meaning of some uncommon mutations when referring to a certain tumor subtype, the results should be better considered as preliminary and worthwhile being further confirmed in future validation tumor series. The five possible phenotypic categories we encountered in our tumor series (TTF1+/p40+ was the only missing phenotype) mirrored to some extent the underlying molecular portrait, which was preferentially relative to ADC or not excluding SQC when considered as a whole thereby allowing a robust biomarker-based classification of LCC to be afforded by T-NGS, independent of gender, age and tumor stage. All phenotypic categories were then a posteriori dissected on the basis of the preferential distribution of underlying gene mutations between ADC and SQC ( Table 4 and S3_Table3), in the premise that DNA mutations were more straightforward and robust than phenotype (potentially affected by epigenetic changes). Accordingly, mutations variably described to cluster in lung ADC, such as ATM, BRAF, EGFR, ERBB4, FBXW7, FLT3, KRAS, NRAF, PTPN11, RET, STK11, SMAD4 and SMO, albeit not completely specific for this tumor type and possibly with meaning of passenger or transitory mutations (destined to be fixed or disappear over time), were distributed as a whole into IHC categories unified by absent or only focal (<10%) expression of p40 irrespective of TTF1 status thereby supporting the ultimate diagnosis of serendipitous ADC or non-squamous NSCLC (a questionable terminology that is however largely used by oncologists for patient treatment), whereas the complete lack of equipollent ADC-related mutations in the three cases featuring TTF1-/p40+ phenotype along with the presence of TP53 mutation (the most frequently mutated gene in SQC) and the cooccurrence of FGFR1 amplification in two out of these three (66%) cases reinforced the likelihood of really facing with undifferentiated SQC 35, 36, 38, 43, 49, 62 . Furthermore, we noted that FGFR1 gene amplification was uncommon (6%) in non-squamous-phenotype tumors of our series with null (TTF1-/p40-) or unclear (TTF1-/p40) phenotype as compared to LCCsquamous (TTF1-/p40+) phenotype (p=0.046) and/or bearing mutations credited to be not so strictly specific for ADC, such as PIK3CA, CDKN2A, FBXW7, FLT3 or SMO (S3_Table 3 and   Fig 2) , indicating that these tumors were really more akin to ADC than SQC differentiation lineage, in keeping with reported prevalence data of low FGFR1 gene amplification in ADC [59] [60] [61] . In other words, even if certain mutations or molecular events are not per se so strictly specific for a given tumor subtype as to be considered transitory or passively passenger tumor determinants, the same mutations or molecular events may become meaningful and coherent with that tumor type as a whole according to the proper IHC context 17, [63] [64] [65] . This managerial approach was proven to be particularly useful in null (13 cases) or unclear (4 cases) phenotypes, which were hard to classify because of the simultaneous absence or unclear expression of decisional biomarkers and the general prudence on the diagnostic interpretation of negative IHC algorithms. On the basis of these findings, we can reasonably exclude aberrant/illegitimate expression of either biomarker in our series of LCC, confirming molecularly the previously proposed IHC axiom "no p40, no squamous" 31, [66] [67] [68] , in keeping to which, whenever there is no expression of p40 in the tumor cell population, the diagnosis of SQC is extremely unlikely..
Notably, our paper indicated that gene mutations were frequent (90%) events in LCC, and that about 40% of patients exhibited multiple mutations (S2_Table 2, Table 3 ). The high mutation rate of LCC correlated with a high frequency of mutated allelic DNA and a tobacco exposure-related signature (our patients were current or former smokers, Table 1 ) in keeping with other lung carcinomas, such as SCLC 69, 70 or ADC 35, 36, 43 . Multiplicity of mutations (S1_Table 1, S2_Table 2 and Table 3 ), while offering alternative options of targeted therapy for these life-threatening tumors (13 of our patients had recurrent disease and 12 died of disease even if 25 (83%) of whom were in stage I-II, see Table 1 and S2_Fig 2), may be responsible for secondary resistance development upon target therapy by selecting tumor clones and for dismal prognosis (Fig 3) likely due to the involvement of tumor suppressor genes and/or accumulating numbers of mutations, as recently suggested by multi-region sequencing studies. 71 .
Robustness of our T-NGS results was confirmed by means of Sanger re-sequencing for common mutations or IHC correlations for selected protein expression such as p53 (S1_Fig 1). The number of genes in our tumor series was greater than previously assessed in other similar works 16, 17, 48, 49 , revealing 16 different gene mutations underlying diverse biological mechanisms (S3_Table 3). Most of these mutations preferentially split into ADC or SQC, but some of the less frequently described mutations in lung cancer and in pulmonary ADC, such as ERBB4, FBXW7, FLT3, NRAS, PTPN11, RET, SMAD4 and SMO, were interpreted as belonging to the ADC category not only on the basis of available gene mutation catalogues and the absence of FGFR1 amplification in these tumors, but also of the relevant IHC profiles all basically dominated by p40 negativity or focal (<10%) occurrence irrespective of TTF-1 status.
It could be speculated that LCC null/unclear phenotypes represent variant of TTF-1 negative ADC, which may account up to 20% of morphological ADC 20 , whereas absence or focal presence of p40 is unlikely to occur in SQC 27, 31 , inasmuch as p40 acts as a master regulator of epidermal cell fate trans-activating genes of basal keratins [66] [67] [68] . In keeping with our findings, other studies dealing with specific microRNA prevalence 18 or different mutation profiles 16, 17 supported the notion that TTF1/p40 double negative LCC would be more akin to ADC, once NE tumors, sarcoma, melanoma or unexpected metastasis was ruled out. Focal p40 decoration in otherwise TTF1-negative LCC showing mutation traits of ADC could even underline focal squamous/basal-like (co)-lineage within individual tumor cells of ADC 31, 63, [72] [73] [74] rather than an aberrant/illegitimate expression of these non-TA isoforms in ADC-differentiated LCC.
Tumor categories unveiled by IHC did not change if different antibodies to p40 were used, whether polyclonal or monoclonal, this indicating that both reagents pinpointed the same tumor cells in keeping with previously reported findings 31 . Gene associations beyond TP53 were seen for KRAS with ATM, FLT3, PTPN11, PIK3CA, STK11 and SMAD4, and for EGFR with FBXW7 ( Table 3 and S1_Table1), suggesting different activation pathways in the development of LCC (S2_Table2), but further investigation on a larger number of LCC is clearly warranted to confirm these preliminary data.
Conclusions
This is a preliminary molecular study based on T-NGS, which suggests -in keeping with IHC findings -that most LCC basically pinpoint ADC with a minority of SQC, and that p40 and TTF1-based IHC profiling is likely to mirror underlying differentiation lineages. This conclusion paves the way to an innovative and clinically oriented classification of LCC 19 resulting from integration of gene mutation and IHC profiles to successfully align with precision medicine requirements (the right drug, to the right patient, at the right time).
Bullet points
1) LCC basically underlie dual cell lineages based on T-NGS and p40/TTF1 profiling 2) ΔNp63-p40 positivity unveils SQC while negativity underpins ADC in keeping with T-NGS to sustain the axiom "no p40, no squamous"
3) Null or unclear phenotype corresponds to ADC by merging molecular and IHC grounds 4) Integrating T-NGS and IHC may result in a clinically oriented classification on LCC 
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